Seres Therapeutics announced encouraging top-line results from an IST evaluating SER-155 in patients with irEC; to host webcast today, July 8, at 8:30 am ET (8.14)
- 80% of SER-155 recipients achieved immunosuppressive-free clinical response of diarrhea (a primary symptom of irEC) at Day 15 in the Investigator-Sponsored Trial (IST) conducted by Memorial Sloan Kettering Cancer Center (MSK)
- SER-155 has potential to treat irEC, a frequent side effect of immune checkpoint inhibitors (ICIs) that often causes halting of cancer treatment, without requiring treatment with systemic immunosuppressive drugs
- SER-155 was well tolerated, with no drug-related serious adverse events observed
- Drug pharmacology data provide confirmatory evidence of Seres' live biotherapeutics operating as designed to repair the mucosal epithelial barrier and reduce gastrointestinal inflammation, which supports possible expansion into multiple other inflammatory and immune diseases